These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 30609798

  • 1. (-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.
    Chen ST, Kang L, Wang CZ, Huang PJ, Huang HT, Lin SY, Chou SH, Lu CC, Shen PC, Lin YS, Chen CH.
    Molecules; 2019 Jan 03; 24(1):. PubMed ID: 30609798
    [Abstract] [Full Text] [Related]

  • 2. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H, Liu T, Li J, Xu J, Chen F, Hu L, Zhang B, Zi C, Wang X, Sheng J.
    Biomed Pharmacother; 2019 Oct 03; 118():109237. PubMed ID: 31376653
    [Abstract] [Full Text] [Related]

  • 3. (-)-Epigallocatechin-3-gallate inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing NF-κB and MAPK signaling pathways.
    Xu H, Liu T, Jia Y, Li J, Jiang L, Hu C, Wang X, Sheng J.
    Int Immunopharmacol; 2021 Jun 03; 95():107464. PubMed ID: 33677256
    [Abstract] [Full Text] [Related]

  • 4. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 03; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 5. Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
    Kats A, Norgård M, Wondimu Z, Koro C, Concha Quezada H, Andersson G, Yucel-Lindberg T.
    J Cell Mol Med; 2016 Jun 03; 20(6):1128-38. PubMed ID: 26987561
    [Abstract] [Full Text] [Related]

  • 6. Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs.
    Kats A, Gerasimcik N, Näreoja T, Nederberg J, Grenlöv S, Lagnöhed E, Desai S, Andersson G, Yucel-Lindberg T.
    J Cell Mol Med; 2019 Feb 03; 23(2):1152-1163. PubMed ID: 30506812
    [Abstract] [Full Text] [Related]

  • 7. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep 03; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 8. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Rédini F.
    Exp Cell Res; 2004 Feb 15; 293(2):292-301. PubMed ID: 14729467
    [Abstract] [Full Text] [Related]

  • 9. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
    Nishioku T, Kubo T, Kamada T, Okamoto K, Tsukuba T, Uto T, Shoyama Y.
    Biomed Res; 2020 Feb 15; 41(6):269-277. PubMed ID: 33268671
    [Abstract] [Full Text] [Related]

  • 10. (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-kappaB.
    Lin RW, Chen CH, Wang YH, Ho ML, Hung SH, Chen IS, Wang GJ.
    Biochem Biophys Res Commun; 2009 Feb 20; 379(4):1033-7. PubMed ID: 19150340
    [Abstract] [Full Text] [Related]

  • 11. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.
    J Nat Med; 2012 Jan 20; 66(1):8-16. PubMed ID: 21656335
    [Abstract] [Full Text] [Related]

  • 12. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB.
    Arthritis Rheum; 2004 Dec 20; 50(12):3831-43. PubMed ID: 15593184
    [Abstract] [Full Text] [Related]

  • 13. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
    Xu H, Chen F, Liu T, Xu J, Li J, Jiang L, Wang X, Sheng J.
    Chem Biol Interact; 2020 Nov 01; 331():109235. PubMed ID: 32971123
    [Abstract] [Full Text] [Related]

  • 14. Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.
    Li B, Lu D, Chen Y, Zhao M, Zuo L.
    Int J Mol Sci; 2016 Apr 22; 17(4):. PubMed ID: 27110777
    [Abstract] [Full Text] [Related]

  • 15. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.
    Bone; 2011 Dec 22; 49(6):1290-8. PubMed ID: 21925296
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice.
    Zhao D, Shu B, Wang C, Zhao Y, Cheng W, Sha N, Li C, Wang Q, Lu S, Wang Y.
    J Cell Biochem; 2020 Jan 22; 121(1):152-164. PubMed ID: 31318102
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B, Wu D, Cheng Y, Huang P, Liu Y, Gan L, Liu C, Cao Y.
    Scand J Immunol; 2020 May 22; 91(5):e12874. PubMed ID: 32090353
    [Abstract] [Full Text] [Related]

  • 20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.